Figure 5.

Heterologous vaccination with VSV-hDCT, followed by Ad-hDCT allowed rapid priming and boosting of the CD8⁺ T-cell response. C57BL/6 mice (n = 5/group) received 1 × 10⁷ plaque-forming units (pfu) of VSV-hDCT, followed 4, 7, or 14 days later by 1 × 10⁸ pfu Ad-hDCT. Single-immunized controls received phosphate-buffered saline on day 0 and 1 × 10⁸ pfu Ad-hDCT on day 14. On day 21, antigen-specific, blood-derived T cells were quantified by flow cytometry after in vitro peptide restimulation and intracellular cytokine staining. The mean fold-increase in percentage of (a) CD4⁺ and (b) CD8⁺ T cells relative to the single-immunized controls are shown. Asterisks denote significant differences (P ≤ 0.05, one-way analysis of variance). Ad, adenovirus; hDCT, human dopachrome tautomerase; VSV, vesicular stomatitis virus.